ما هو علاج التهاب المهبل الضموري لجفاف المنطقة الفرجية المهبلية وألم الجماع والتهيج؟

DOI: 10.1097/JU.0000000000004589

• Clinicians should offer the option of local low-dose vaginal estrogen to patients with GSM to improve vulvovaginal discomfort/irritation, dryness, and/or dyspareunia.
• Local low-dose vaginal estrogen may be administered in the form of a cream, tablet, or ring and can be used to improve vaginal dryness, dysuria, dyspareunia, and vulvovaginal discomfort/irritation related to GSM.
• Clinicians should offer the option of vaginal dehydroepiandrosterone (DHEA) to patients with GSM to improve vulvovaginal dryness and/or dyspareunia.
• Clinicians may offer the option of ospemifene to patients with GSM to improve vulvovaginal dryness and/or dyspareunia.
• Clinicians should recommend the use of vaginal moisturizers and/or lubricants, either alone or in combination with other therapies, to improve vaginal dryness and/or dyspareunia in patients with GSM.
• Clinicians should counsel patients to avoid vulvovaginal irritants and/or cleansers which may exacerbate the signs and symptoms of GSM.
• For effective treatments, limited evidence and clinician experience suggest that symptoms begin improving within 1 to 2 months of initiating treatment and continue to improve through 12 weeks (average length of study follow-up).